Avalanche Biotechnologies beats by $0.01, misses on revenue

1 message picture_as_pdf Source PDF

R

To

jeffrey E.

Aug 13 2015, 16:45 ET | About: Avalanche Biotechnologies (AAVL) | By: Mohit Manghnani, SA News Editor

Avalanche Biotechnologies (NASDAQ:AAVL): Q2 EPS of -$0.38 beats by $0.01.

Revenue of $0.2M (+42.9% Y/Y) misses by $0.56M.

Shares -13.2%.

http://seekingalpha.com/pr/14409436-avalanche-biotechnologies-inc-reports-second-quarter-2015-financial-results-and-provides-update-on-avaminus-101-program

Richard Kahn
HBRK Associates Inc.
575 Lexington Avenue 4th Floor
New York, NY 10022
tel 212-971-1306
fax 646-350-0954
cell 917-414-7584